Skip to main content

New hope treatment in familial hypercholesterolemia

New hope comes today for those with familial hypercholesterolemia (FH).

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease.



Without treatment, the life expectancy of those with familial hypercholesterolemia can be reduced by approximately 15-30 years. However, in people with homozygous familial hypercholesterolemia, life expectancy may only be 20 years or less.

Homologous chromosomes come in pairs. One homologous chromosome is inherited from the mother; the other is inherited from the father.  Homozygous refers to a gene that has identical alleles on both homologous chromosomes.   This is why the homozygous condition is particularly rare and can be more severe.

HoFH is a rare and more severe form of familial hypercholesterolemia (FH), an inherited condition characterized by very high levels of LDL-C and premature cardiovascular disease.

Inheriting FH- causing mutations from both parents results in HoFH in the child. HoFH is an extremely severe condition and is often associated with aggressive and markedly premature heart disease, including coronary artery disease and aortic valve disease. 

Children and teenagers with HoFH may have heart attacks or angina requiring the insertion of coronary stents or heart bypass surgery.

A new study shows that adding Praluent® (alirocumab) significantly reduced cholesterol levels by 35.6 per cent, compared to other lipid-lowering therapies alone, in patients with homozygous familial hypercholesterolemia.

The results of the placebo-controlled trial were presented at the joint meeting of the American College of Cardiology (ACC.20) together with the World Congress of Cardiology (WCC) Scientific Sessions.

Results showed treatment with Praluent significantly reduced other lipoprotein and lipid measures associated with elevated cardiovascular risk, including apolipoprotein B [29.8 percent (p<0.0001)], total cholesterol [26.5 percent (p<0.0001)], non-high-density lipoprotein cholesterol (HDL-C) [32.9 percent (p<0.0001)] and lipoprotein(a) [28.4 percent (p<0.0001)] versus placebo.

Lead investigator Dr Dirk Blom says,

“These results demonstrate a statistically significant and clinically-meaningful reduction in LDL-C levels after 12 weeks and have the potential to expand treatment options for very high-risk patients with this serious condition.”



Comments

Popular posts from this blog

Ian Duncan-Smith says he wants to make those on benefits 'better people'!

By any account, the government's austerity strategy is utilitarian. It justifies its approach by the presumed potential ends. It's objective is to cut the deficit, but it has also adopted another objective which is specifically targeted. It seeks to drive people off benefits and 'back to work'.  The two together are toxic to the poorest in society. Those least able to cope are the most affected by the cuts in benefits and the loss of services. It is the coupling of these two strategic aims that make their policies ethically questionable. For, by combining the two, slashing the value of benefits to make budget savings while also changing the benefits system, the highest burden falls on a specific group, those dependent on benefits. For the greater good of the majority, a minority group, those on benefits, are being sacrificed; sacrificed on the altar of austerity. And they are being sacrificed in part so that others may be spared. Utilitarian ethics considers the ba

Prioritising people in nursing care.

There has been in recent years concern that care in the NHS has not been sufficiently 'patient centred', or responsive to the needs of the patient on a case basis. It has been felt in care that it as been the patient who has had to adapt to the regime of care, rather than the other way around. Putting patients at the centre of care means being responsive to their needs and supporting them through the process of health care delivery.  Patients should not become identikit sausages in a production line. The nurses body, the Nursing and Midwifery Council has responded to this challenge with a revised code of practice reflection get changes in health and social care since the previous code was published in 2008. The Code describes the professional standards of practice and behaviour for nurses and midwives. Four themes describe what nurses and midwives are expected to do: prioritise people practise effectively preserve safety, and promote professionalism and trust. The

When Finance Drives Destruction

Tackling climate change means stopping the funding of rainforest destruction, says a significant study commissioned by the World Wildlife Fund.  The UK's financial services have provided directly over £8.7 billion to 167 different traders, processors, and buyers of forest-risk commodities (cocoa, rubber, timber, soy, beef, palm oil, pulp & paper) from 2013 to 2021.   With direct and indirect investment,  the figure rises to a staggering £200 bn.  Whilst not all that investment is in destructive projects,  the study concludes there is little transparency on the risk.  Finance is the oil in the economic machine.  But it also drives decisions. We all know the importance of money. We borrow to invest. So much depends on it, such as company pensions.  Do we really know what our pension pots are doing? We invest for the future. But what kind of future? Is all investment good?  Much investment is bad. Investment drives the nature of our economy. It drives our decisions as individuals,